Literature DB >> 7988727

Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes.

M Ramani1, F Khechai, V Ollivier, C Ternisien, F Bridey, J Hakim, D de Prost.   

Abstract

Fibrin deposition is an integral feature of the inflammatory response. In response to C-reactive protein (CRP), an acute-phase reactant, blood monocytes synthesize and express tissue factor (TF), the main initiator of blood coagulation. We report the inhibitory effect of interleukin 10 (IL-10) and that of pentoxifylline, a methyl xanthine derivative, on monocyte expression of TF activity, TF protein and TF mRNA in response to CRP. These agents may be of use in diseases where a TF-induced prothrombotic state is detrimental.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988727     DOI: 10.1016/0014-5793(94)01236-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Interleukin-10 regulates the tissue factor activity of monocytes in an in vitro model of bacterial endocarditis.

Authors:  M H Veltrop; J A Langermans; J Thompson; M J Bancsi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Authors:  J M Reimund; S Dumont; C D Muller; J S Kenney; M Kedinger; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

3.  C-reactive protein is expressed and secreted by peripheral blood mononuclear cells.

Authors:  D G Haider; N Leuchten; G Schaller; G Gouya; J Kolodjaschna; L Schmetterer; S Kapiotis; M Wolzt
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

4.  Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).

Authors:  Soheil Mansourian; Payvand Bina; Arezoo Fehri; Abbas Ali Karimi; Mohammad Ali Boroumand; Kyomars Abbasi
Journal:  Anatol J Cardiol       Date:  2014-12-31       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.